Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), today announced the conclusion of their collaboration with a very positive outcome.The purpose of the collaboration was to explore the anti-tumor efficacy of the CD40 antibody mitazalimab in chemotherapy-resistant preclinical tumor models as an addition to chemotherapy (FOLFIRINOX) combined with SCO-101. The hypothesis that was tested was to see if SCO-101, as compared to saline control will revert chemotherapy resistance and thereby facilitate a